Skip to main content

IMPORTANT SAFETY INFORMATION 

Myelosuppression

  • Thrombocytopenia, neutropenia, and anemia, including grade 3/4 reactions, have occurred in patients receiving SCEMBLIX

  • Perform complete blood counts every 2 weeks for the first 3 months of treatment and monthly thereafter or as clinically indicated. Monitor patients for signs and symptoms of myelosuppression...

INDICATIONS

SCEMBLIX is indicated for the treatment of adult patients with:

  • Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with 2 or more tyrosine kinase inhibitors (TKIs)

  • Ph+ CML in CP with the T315I mutation...

Click or scroll to see IMPORTANT SAFETY INFORMATION AND INDICATIONS
References: 1. Scemblix. Prescribing information. Novartis Pharmaceuticals Corp. 2. Data on file. CABL001A2301 clinical study report. Novartis Pharmaceuticals Corp; 2022. 3. Data on file. CABL001A Week 96 SCS. Novartis Pharmaceuticals Corp; 2022. 4. Hochhaus A, Réa D, Boquimpani C, et al. Leukemia. 2023;37(3):617-626.